Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab and sulfasalazine for PET/CT-detected axial and aortic inflammation in axial spondyloarthritis
2015-000752-20Phase 4Completed
- Sponsor
- University of Helsinki
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of adalimumab and 5-aminosalicylic acid + sulphasalazine in axial spondyloarthritis (axSpA) (4 arms), sponsored by University of Helsinki. Primary endpoint: Change in PET signal in cardiovascular and musculoskeletal tissues. Started Jul 2015; status: completed.
02
Drugs
adalimumab5-aminosalicylic acid + sulphasalazine
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2015-000752-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000752-20.